Kestra insider plans sale of 8,752 KMTS shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. (KMTS) has a notice from insider Traci Umberger indicating an intent to sell up to 8,752 shares of common stock through Merrill Lynch on or after July 31, 2026 on NASDAQ. These shares are tied to the July 17, 2026 vesting of performance share unit awards, granted as part of the company’s equity compensation program.
The filing also reports that Umberger sold 5,887 shares of common stock on July 30, 2026 for 133,892.22 during the prior three months, providing recent trading history associated with this insider’s holdings.
Key Figures
Key Terms
Form 144 regulatory
equity compensation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for KMTS disclose about planned stock sales?
What prior KMTS stock sale is reported in the last three months?
AI-generated analysis. How Rhea-AI works. Not financial advice.